GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Notes Receivable

Lumos Diagnostics Holdings (ASX:LDX) Notes Receivable : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Notes Receivable?

Lumos Diagnostics Holdings's Notes Receivable for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Lumos Diagnostics Holdings Notes Receivable Historical Data

The historical data trend for Lumos Diagnostics Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Notes Receivable Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23
Notes Receivable
- -

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial - - - - -

Lumos Diagnostics Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Lumos Diagnostics Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Diagnostics Holdings (ASX:LDX) Business Description

Traded in Other Exchanges
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines